The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies-Reference-Cited by-同舟云学术

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies

Published:2014-09-26 Issue:1 Volume:14 Page:
ISSN:1471-2261
Container-title:BMC Cardiovascular Disorders
language:en
Short-container-title:BMC Cardiovasc Disord

Author:

Varas-Lorenzo Cristina,Margulis Andrea V,Pladevall Manel,Riera-Guardia Nuria,Calingaert Brian,Hazell Lorna,Romio Silvana,Perez-Gutthann Susana

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1186/1471-2261-14-129.pdf

Reference71 articles.

1. Defronzo RA: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009, 58: 773-795. 10.2337/db09-9028.

2. Moller DE, Flier JS: Insulin resistance–mechanisms, syndromes, and implications. N Engl J Med. 1991, 325: 938-948. 10.1056/NEJM199109263251307.

3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F: European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012, 19: 403-488. 10.1007/s12529-012-9242-5.

4. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, et al: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007, 28: 88-136.

5. Lehman R, Yudkin JS, Krumholz H: Licensing drugs for diabetes. BMJ. 2010, 341: c4805-10.1136/bmj.c4805.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model;Health Economics Review;2023-10-25

2. An examination of psychometric properties of study quality assessment scales in meta-analysis: Rasch measurement model applied to the firefighter cancer literature;PLOS ONE;2023-07-26

3. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-03-29

4. Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM;Diabetes and Cardiovascular Disease;2023

5. Comparative safety of sulfonylureas among U.S. nursing home residents;Journal of the American Geriatrics Society;2022-12-10